Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CKLSF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32 Med: 0.39 Max: 0.45
Current: 0.32
During the past 13 years, the highest Equity to Asset Ratio of CK Life Sciences International Holdings was 0.45. The lowest was 0.32. And the median was 0.39.
CKLSF's Equity-to-Asset is ranked worse than 77.86% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs CKLSF: 0.32
CK Life Sciences International Holdings (OTCPK:CKLSF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CK Life Sciences International Holdings Equity-to-Asset Related Terms
CK Life Sciences International Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Equity-to-Asset Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Equity-to-Asset vs Biotechnology Industry
CK Life Sciences International Holdings Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (CKLSF) has a Equity-to-Asset of 0.32 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CK Life Sciences International Holdings and its competitors. This is 18% below median its historical median of 0.39. Over the past decade, CK Life Sciences International Holdings' Equity-to-Asset has ranged from 0.32 to 0.45. According to the industry distribution chart, CK Life Sciences International Holdings ranks #1101 out of 1414 companies in the Biotechnology industry, placing it in the top 77.9%.
Is CK Life Sciences International Holdings' Equity-to-Asset too high?
CK Life Sciences International Holdings' current Equity-to-Asset of 0.32 is 18% below median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.45. The Biotechnology industry median Equity-to-Asset is 0.68. CK Life Sciences International Holdings' value of 0.32 is 52.9% below this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #1101 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #1101 out of 1414 companies for Equity-to-Asset. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. CK Life Sciences International Holdings' value of 0.32 is 52.9% below this benchmark. Historically, CK Life Sciences International Holdings' own Equity-to-Asset has ranged from 0.32 to 0.45 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.68, CK Life Sciences International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Equity-to-Asset of 0.32 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Equity-to-Asset is 0.32, which is 18% below median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Equity-to-Asset of 0.32. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Equity-to-Asset is 0.32, which is 18% below median its 10-year median of 0.39 and 52.9% below the Biotechnology industry median of 0.68. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Equity-to-Asset is 0.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
Equity-to-Asset: 0.32 (18% below median its 10-year median of 0.39)
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
Industry Position: 52.9% below the Biotechnology median (#1101 of 1414)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for CKLSF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
